Osteoporosis
Conference Coverage
Treatment sequence with romosozumab influences osteoporosis outcomes
Administering anabolic agents followed by antiresorptives is associated with higher gains in bone mineral density and improved bone-turnover...
Conference Coverage
Biologics may protect psoriasis patients against severe COVID-19
Preliminary evidence suggests biologics prevent the fearsome COVID-19 late cytokine storm.
Conference Coverage
Longer bisphosphonate use ups AFF risk, but not all is tied to drug
The clinical implications of research to date are that “the risk of AFF should not dissuade patients and providers from short-term use of...
Conference Coverage
Treat-to-target strategy ‘not ready for primetime’ in osteoporosis
Debaters at a session of the recent virtual ASBMR 2020 annual meeting could have gone either way on this topic, but data and evidence are...
From the Journals
CagA-positive H. pylori patients at higher risk of osteoporosis, fracture
Study adds additional weight to previous findings regarding H. Pylori infection and bone fragility, particularly among CagA-positive...
From the Journals
Atypical fractures with bisphosphonates highest in Asians, study confirms
The benefits of bisphosphonates in fracture reduction still far outweigh risks for atypical femur fractures, but the study shows a higher risk for...
From the Journals
SGLT2 inhibitors with metformin look safe for bone
A meta-analysis of clinical trials finds no significant increase in fracture rate in type 2 diabetes patients taking SLGT-2 inhibitors plus...
From the Journals
Fracture risk prediction: No benefit to repeat BMD testing in postmenopausal women
But experts advise against a broad recommendation to skip repeat testing in the general population.
From the Journals
Low vitamin D linked to increased COVID-19 risk
A large study evaluates associations between low serum vitamin D levels and risks for acquiring COVID-19 and hospitalization.
Latest News
Delaying denosumab dose boosts risk for vertebral fractures
Physicians say patients may skip regular injections of the osteoporosis drug amid the pandemic.
From the Journals
Bisphosphonates may have limited ‘protective’ effect against knee OA progression
Women who used bisphosphonates were half as likely as those who did not to experience radiographic progression at 2-year follow up.